This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by DeVita, V. T. Articles by Chu, E. Search for Related Content PubMed PubMed Citation Articles by DeVita, V. T., Jr. Articles by Chu, E. Related Collections Historical Overview

A History of Cancer Chemotherapy

Yale Cancer Center, Yale University School of Medicine, New Haven Connecticut

Requests for reprints: Vincent T. DeVita, Jr. or Edward Chu, Yale Cancer Center, Yale University School of Medicine, 333 Cedar Street, New Haven, CT 06520. Phone: 203-787-1010; Fax: 203-785-2875; E-mail: vincent.devita{at}yale.edu or chueyale{at}yahoo.com.

Key Words: chemotherapy

Abstract

The use of chemotherapy to treat cancer began at the start of the 20th century with attempts to narrow the universe of chemicals that might affect the disease by developing methods to screen chemicals using transplantable tumors in rodents. It was, however, four World War II–related programs, and the effects of drugs that evolved from them, that provided the impetus to establish in 1955 the national drug development effort known as the Cancer Chemotherapy National Service Center. The ability of combination chemotherapy to cure acute childhood leukemia and advanced Hodgkin's disease in the 1960s and early 1970s overcame the prevailing pessimism about the ability of drugs to cure advanced cancers, facilitated the study of adjuvant chemotherapy, and helped foster the national cancer program. Today, chemotherapy has changed as important molecular abnormalities are being used to screen for potential new drugs as well as for targeted treatments. [Cancer Res 2008;68(21):8643–53]

This article has been cited by other articles:

				E. Briasoulis, P. Pappas, C. Puozzo, C. Tolis, G. Fountzilas, U. Dafni, M. Marselos, and N. Pavlidis Dose-Ranging Study of Metronomic Oral Vinorelbine in Patients with Advanced Refractory Cancer Clin. Cancer Res., October 15, 2009; 15(20): 6454 - 6461. [Abstract] [Full Text] [PDF]

				S. M. Lippman and E. T. Hawk Cancer Prevention: From 1727 to Milestones of the Past 100 Years Cancer Res., July 1, 2009; 69(13): 5269 - 5284. [Abstract] [Full Text] [PDF]